Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3460

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3460
---
 partners. In addition,
we expect to access laboratory facilities and resources through various CRO partners such as Lonza with whom we are currently engaged.

We
believe that our access to preclinical and clinical research facilities are adequate for our current needs and that suitable facilities
at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.

Legal
Proceedings

From
time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of the date of this Annual
Report on Form 10-K, we were not a party to any material legal matters or claims except as set forth in our audited financial statements
for the year ended December 31, 2024, as included in this Annual Report.

In
the future, we may become party to legal matters and claims in the ordinary course of business, the resolution of which we do not anticipate
would have a material adverse impact on our financial position, results of operations or cash flows except as set forth in our audited
financial statements for the year ended December 31, 2024, as included in this Annual Report.

66

Status
as a Public Company

We
are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As such,
we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not “emerging growth companies” including, but not limited to, not being required to comply with the independent
registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find
our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities
may be more volatile.

In
addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended
transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other
words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We